Original antigenic sin describes a phenomenon in which the antibody response elicited in an individual after a secondary viral infection reacts more strongly to the viral variant that originally infected the individual. As T helper cells play critical roles in promoting antibody responses, a similar phenomenon may hold true for T helper cell responses. This concept is particularly relevant to the development of vaccines against viruses such as human immunodeficiency virus and hepatitis C virus, in which myriad viral variants are present throughout the human population. We have compared the effects of priming the immune system with a single peptide epitope or with a cocktail of related peptides based on the epitope. Our data demonstrate that immunization with multiple peptide variants expands a more broadly reactive and durable T helper cell response than does immunization with a single peptide. This vaccine strategy may circumvent original antigenic sin.
INTRODUCTION
An effective vaccine against human immunodeficiency virus (HIV) will likely need to expand virusspecific T helper cell, cytotoxic T lymphocyte (CTL), and antibody responses. T helper cell proliferative responses against HIV or simian immunodeficiency virus (SIV) antigens correlate with reduced viral loads and delayed progression to disease (1) (2) (3) (4) . This observation is not surprising given that in addition to their longestablished role in providing B cell help, T helper cells play critical roles in generating and maintaining CTL activity in vivo (5) (6) (7) . Strong CTL responses are associated with lower viral loads and neutralizing antibodies can protect against viral challenges (8 -15) .
Two problems that have vexed the HIV vaccine field are the inability to elicit broadly reactive neutralizing antibody responses and the relatively short duration of cellular and humoral immunity elicited with candidate HIV vaccines (16) . We have previously described a vaccine approach that uses degenerative peptide cocktails, termed hypervariable epitope constructs (HECs). HECs are based on hypervariable epitopes of the envelope glycoproteins of HIV or SIV and are used to elicit broadly reactive, long-lasting neutralizing antibody responses (17, 18) . In the present study we compared the ability of a HEC based on the hypervariable V3 region of HIV with a peptide based on a single isolate of HIV to similarly expand broadly reactive T helper cell responses. Our results demonstrate that immunization of mice with a HEC expanded T cells that were more broadly reactive than did mice immunized with the single peptide. Significantly, the T cell repertoire expanded after HEC immunization was more durable than the repertoire expanded after immunization with the single peptide and recognized naturally processed antigen more readily.
MATERIALS AND METHODS

Design of HECs and Peptide Synthesis
The design and synthesis of the HECs based on the V3 loop of HIV-1 gp120 and on the V4 loop of SIV gp130 have been described extensively elsewhere (17, 18) . Briefly, in the design of the HECs, sequences obtained from the Los Alamos Human Retroviruses and AIDS Database for the two regions of interest were aligned. The most common amino acids at each position along the region of interest were selected for addition during the peptide synthesis, based on the frequency with which they occurred among clade B strains of HIV-1 (HEC V3) or among strains of SIVmac and SIVsm (HEC V4). The peptide mixtures were synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry utilizing high-capacity (0.7 mmol/g) Knorr resin (Advanced ChemTech, Inc., Louisville, KY) with 1% divinylbenzene crosslinker. Standard Fmoc chemistry was used for the synthesis of the MN V3, RF V3, V4 (142), and V4 (239) peptides. Their sequences are provided in Table 1 . Amino acid analysis ensured the presence of the expected amino acids in all peptides and HECs.
Immunization of Mice
Balb/c mice 6 -8 weeks old were housed in conventional facilities and immunized twice with 100 g of peptide or HEC, the second immunization occurring three weeks after the first. They were immunized with peptides or HECs mixed at a 1:1 ratio with the adjuvant Montanide ISA-51 (Seppic, Paris, France) and PBS, in a final volume of 100 l/mouse. This oil-based adjuvant has been approved for use in humans. Subcutaneous immunization was performed at the base of the tail.
Quantitation of Antigen-Specific T Helper Cells
Two weeks and two months after a second immunization, mice were sacrificed and their spleens and draining lymph nodes were harvested. Isolated cells (2 ϫ 10 6 /ml) were left unstimulated or stimulated with indicated peptides or HECs at a final concentration of 10 g/ml. Purified whole inactivated SIVmac251 virus (ABI, Columbia, MD) was used at 5 g/ml. An irrelevant negative control peptide derived from Type D simian retrovirus was used as an additional negative control. Typically there was little difference in the frequency of CD69 ϩ T cells left unstimulated or stimulated with the negative control peptide. After 16 h in a 37°C CO 2 incubator, cells were collected, washed with PBS, and stained with anti-CD4-FITC and anti-CD69-PE monoclonal antibodies (Caltag, Burlingame, CA) according to the manufacturer's recommendations. The frequency of T helper cells specific for each antigen was determined by calculating the percentage of CD4 ϩ T cells that were also CD69 ϩ (a marker of T cell activation). Typically, 100,000 events were collected from splenocyte samples and 25,000 events from lymph node samples. Expression of CD69 induced by stimulation with irrelevant peptide was subtracted from all values. The frequency of antigen-specific splenocytes and lymph node cells for each animal was calculated individually. These two values were added to arrive at a total frequency of antigen-specific T cells for each animal. Statistical significance among different immunization and stimulation conditions was determined with a Mann-Whitney test using GraphPad Instat 2.03 for Mac, GraphPad Software (San Diego, CA).
RESULTS
Broadly Reactive and Durable T Cell Memory Elicited with a Hypervariable Epitope Construct
Hypervariable epitope constructs are degenerative peptide cocktails that are made in a single synthesis reaction and that are based on hypervariable B cell and T helper cell epitopes. Their design and ability to elicit broadly reactive neutralizing antibodies in mice, rabbits, and nonhuman primates have been described extensively elsewhere (17, 18) . In the current study we wished to determine whether immunization of mice with a HEC based on the V3 loop of HIV-1 clade B viruses could similarly expand broadly reactive T helper cell responses. We compared T cell responses elicited by the V3 HEC to those elicited with a single peptide based on the V3 loop of the HIV-1 MN strain of Table 1 ; the sequence of the V3 loop of the HIV-1 RF strain of virus, which was used to assess reactivity to a heterologous epitope, is also provided. The HEC V3 is predicted to contain 64 different peptides, which represent the most commonly occurring epitope variants based on available in vivo sequence data.
Mice were immunized twice with the HEC V3 or with the MN V3 peptide and T cell responses were measured against HEC V3, MN V3, or RF V3 2 weeks and 2 months after the second immunization. We determined the number of peptide-specific T helper cells using flow cytometry by quantitating the number of CD4 ϩ T cells that were also CD69 ϩ after 16 h of stimulation in vitro with the indicated peptides. We assessed antigen specificity by measuring expression of CD69 rather than secretion of IFN-␥. This marker of early T cell activation was chosen because, in contrast to viral infections that strongly polarize the T helper cell response toward Th1 cytokine profile (and IFN-␥ secretion), we were not sure that the majority of antigen-specific T cells expanded by peptide immunization in oil-based adjuvant would similarly result in a polarized Th1 response.
As expected, immunization of mice with the MN V3 peptide expanded a high frequency (mean frequency, 4.9%) of T cells present 2 weeks after the second immunization that were specific for the MN V3 peptide (Fig. 1A) . This robust T cell response was not surprising, given the known immunogenicity of this region of the HIV-1 envelope protein. Despite the high frequency of T cells specific for the MN V3 peptide, 10-fold fewer T helper cells reacted with the RF V3 peptide (mean frequency, 0.4%) or with related peptides contained within the HEC V3 (mean frequency, 0.5%). By comparison, whereas immunization of mice with the HEC V3 expanded a lower frequency of T cell specific to itself (mean frequency, 0.8%), there were comparable frequencies of T cells specific for both the MN V3 and RF V3 peptides (mean frequencies of 0.6 and 0.8%, respectively). As measured 2 weeks after the secondary immunization, there was not a statistically significant quantitative difference in the ability of MN V3-vs HEC V3-immunized mice to recognize the heterologous RF V3 peptide. Noteworthy is the observation that only a small fraction (approximately 10%) of the T cell repertoire expanded with and specific to the MN V3 peptide reacted with the RF peptide, whereas a comparable number of T cells expanded with and specific to the HEC V3 reacted with the RF peptide. These data suggest that immunization with the MN V3 peptide expanded a larger repertoire of T cells with a more limited breadth of reactivity, whereas immunization with the HEC V3 elicited a smaller repertoire of T cells that possessed a greater breadth of reactivity.
The high frequency of T cells specific for MN V3 in MN V3-immunized mice was rapidly lost over the course of 6 weeks (Fig. 1A) . There was an approximately 10-fold reduction in the number of T cells present 2 weeks vs 2 months after immunization (mean frequencies of 4.9 vs 0.4%, P Ͻ .001). The modest reactivity to the RF V3 peptide present at 2 weeks declined approximately 2-fold (mean frequencies of 0.4 vs 0.2%). In contrast, the frequencies of T cells specific for the HEC V3 or the MN V3 or RF V3 peptides were statistically comparable 2 weeks and 2 months after immunization with the HEC V3 (0.8 vs 1.5%, 0.6 vs 1.2%, 0.8 vs 1.2%, respectively, Fig. 1B) . Indeed, 2 months after the secondary immunization there were statistically greater frequencies of T helper cells specific for the MN V3 and RF V3 peptides in the The experiments were repeated twice, and the combined results are depicted. Ten mice immunized with MN V3 were analyzed at 2 weeks and 17 mice at 2 months; 9 mice immunized with HEC V3 were analyzed at 2 weeks and 11 mice at 2 months.
154
HEC-immunized mice (P Ͻ .05 and P Ͻ .01, respectively). These data confirm that immunization with the HEC V3 expanded a repertoire of T helper cells with broader reactivity than did immunization with a single peptide. Moreover, they indicate that the memory response elicited by the HEC V3 was more durable than that expanded by the MN V3 peptide.
T Cells Expanded with a HEC Recognize a Naturally Processed Viral Epitope
We wanted to demonstrate that the broad T cell reactivity elicited by immunization with the HEC based on the hypervariable V3 loop of HIV-1 held true for other hypervariable epitopes as well. Moreover, we wanted to determine whether T cells expanded with HEC immunization could recognize naturally processed viral antigen. To address these issues, we immunized mice with a HEC based on a hypervariable epitope of the V4 loop of SIV (HEC V4). For comparison, we used a peptide based on the V4 loop epitope derived from the SIVmac239 strain of virus, V4 (239). Two weeks after secondary immunizations with the HEC V4 or the V4 (239) peptide, we evaluated the frequency of T cell specific for the V4 (239) peptide, a related heterologous peptide, V4 (142), and for naturally processed peptide derived from whole inactivated SIVmac251 virus.
As expected, the V4 (239) peptide induced a greater frequency of T cell specific for itself (4.2%) than did the HEC V4 (1.8%) (Fig. 2) . However, consistent with our previous results, a greater frequency of T cells present in HEC V4-immunized mice recognized the V4 (142) peptide (2.0%) than in V4 (239)-immunized mice (0.7%) (P Ͻ .05). Most importantly, the HEC-immunized mice on average contained 10-fold greater numbers of T cells that could recognize naturally processed SIVmac251 peptide antigen (2.3%) than did mice immunized with a single peptide (0.3%) (P Ͻ .05). Thus, comparable results were obtained in two different viral systems based on two different epitopes.
DISCUSSION
Based on cloning of rearranged T cell receptor genes in primary and secondary responses, repeated protein immunizations were found to limit the diversity of the responding T cell repertoire (19) . These results suggest that not all reactive T cell clonotypes present to respond in a primary response are ultimately involved in memory responses. Moreover, they imply that a less diverse memory repertoire is likely composed of T cells that are less cross-reactive. Similarly, studies of numerous viral infections of humans and mice have demonstrated that CTL responses to given viral epitopes can be very focused (20, 21) .
These data can help explain the phenomena of original antigenic sin that was originally described in the 1950s. While characterizing the antibody responses of individuals vaccinated with an influenza vaccine, many vaccinated individuals subsequently became infected with a heterologous strain of influenza. To the surprise of immunologists studying the humoral responses to influenza in these patients, exposure to the second heterologous virus boosted immunity against the first (vaccine) strain of the virus, with only modest responses directed against the heterologous virus. This phenomena was termed original antigenic sin and was demonstrated in both humans and animals (22, 23) . More recently, Klenerman and Zinkernagel and colleagues have also demonstrated the phenomenon of original antigenic sin using lymphocytic choriomeningitis virus (LCMV) infection of mice (24) . The authors examined secondary (memory) CTL responses to LCMV after infection with a variant LCMV. Secondary infection of mice with a variant virus elicited a response to the parental virus (and its epitopes) with which the mice were first infected; this held true for various parental and variant viruses and their epitopes, as well as for both dominant and subdominant epitopes.
Original antigenic sin could represent a major obstacle to the generation of efficacious HIV vaccines (25) . For example, the only candidate HIV vaccine in Phase III clinical studies involves multiple immunizations with a vaccine composed of recombinant envelope proteins from only two strains of virus. It is not unreasonable to predict that this vaccination approach will serve to expand and focus B cell and T helper cell repertoires specific to epitopes derived from these two strains of virus. Given the tremendous number of HIV variants circulating throughout the human population, ϩ T cells present 2 weeks after the second immunization for each mouse is depicted as a filled circle; the mean frequency is depicted as a horizontal line.
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OVERCOMING ORIGINAL (ANTIGENIC) SIN however, it is unlikely that patients will encounter vaccine strains of virus. If original antigenic sin is operational in these vaccinated individuals, it may significantly delay or preclude antibody and T helper cell responses elicited against infecting, heterologous strains of HIV.
Our data demonstrate that immunization with a single peptide (MN V3 or V4 (239)) expands a higher frequency of T cells specific for that peptide than does immunization with a cocktail of related peptide variants (HEC V3 or HEC V4). However, the T cell repertoire expanded with a single peptide contained relatively few T helper cells capable of recognizing related heterologous peptides compared with the repertoire expanded with a HEC. These data demonstrate that when the immune system is primed with a large array of epitope variants, it expands a broadly reactive T helper cell repertoire. Consistent with these results, we have previously characterized antibody responses with similarly broad reactivities in nonhuman primates immunized with HIV-and SIV-based HECs (17, 18) .
Our data also demonstrate that T cells expanded with the HEC V3 with specificity for related singlepeptide epitopes (MN V3 or RF V3) persisted longer in vivo than did T cells expanded with the MN V3 peptide. At present we are unsure how to explain the enhanced durability of the T helper cell memory response expanded by the HEC V3. Based on murine CTL responses to viral infections in vivo, it has been suggested that the size of the final memory population is proportional to the clonal burst size of the responding CTL repertoire (26) . These data would predict that greater frequencies of T helper cell should be detected 2 months after the secondary immunization with the MN V3 peptide because it would have expanded a greater frequency of T cells 2 weeks after the secondary immunization. Our data, however, do not support this prediction. One explanation may be that the broadly reactive T cell repertoire expanded by the HEC V3 can be stimulated and thus maintained more readily in vivo because individual T cells can respond to low levels of multiple different endogenous peptides present on the surface of antigen-presenting cells in vivo.
Ultimately, these data imply that vaccines that seek to expand broadly reactive T helper cell (or antibody) repertoires should do so by priming and expanding the immune system with multiple peptide or recombinant protein variants rather than with one or a few variants.
